Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias

Brain Pathology

Volumn 25, Issue 4, 2015, Pages 401-408

  Howlett, David R ^a   Whitfield, David ^a   Johnson, Mary ^b   Attems, Johannes ^b   O'Brien, John T ^c   Aarsland, Dag ^d,e   Lai, Mitchell K P ^f   Lee, Jasinda H ^f   Chen, Christopher ^f   Ballard, Clive ^a   Hortobágyi, Tibor ^a,g   Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Alzheimer's disease; cognitive decline; dementia with Lewy bodies; Lewy body dementia; Parkinson's disease dementia

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN; AMYLOID BETA PROTEIN;

ADULT; AGED; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MIDDLE TEMPORAL GYRUS; MINI MENTAL STATE EXAMINATION; NEOCORTEX; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PATHOLOGY SCORE; PREFRONTAL CORTEX; QUANTITATIVE STUDY; SCORING SYSTEM; SENILE PLAQUE; TEMPORAL LOBE; AMYLOID PLAQUE; BRAIN; COGNITION DISORDERS; COMPLICATION; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PLAQUE, AMYLOID; TAU PROTEINS;

EID: 84931561308     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12182     Document Type: Article

References (49)

1. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C, (2005) Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 58: 773-776.
2. Alafuzoff I, Gelpi E, Al-Sarraj S, Arzberger T, Attems J, Bodi I, et al (2012) The need to unify neuropathological assessments of vascular alterations in the ageing brain: multicentre survey by the BrainNet Europe consortium. Exp Gerontol 47: 825-833.
3. Attems J, Jellinger K, (2013) Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res 10: 569-577.
4. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al (2006) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67: 1931-1934.
5. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E, (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
6. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ, (2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74: 77-84.
7. Campbell MC, Markham J, Flores H, Hartlein JM, Goate AM, Cairns NJ, et al (2010) Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 81: 520-527.
8. Cato MA, Crosson B, Gokcay D, Soltysik D, Wierenga C, Gopinath K, et al (2004) Processing words with emotional connotation: an FMRI study of time course and laterality in rostral frontal and retrosplenial cortices. J Cogn Neurosci 16: 167-177.
9. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, Laferla FM, Clinton LK, et al (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30: 7281-7289.
10. Colom-Cadena MM, Gelpi EM, Charif SB, Belbin OP, Blesa RM, Marti MJM, et al (2013) Confluence of [alpha]-synuclein, tau, and [beta]-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72: 1203-1212.
11. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134: 500-505.
12. Cummings JL, (2004) Dementia with Lewy bodies: molecular pathogenesis and implications for classification. J Geriatr Psychiatry Neurol 17: 112-119.
13. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, et al (1999) Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol 56: 1254-1261.
14. Duda JE, (2004) Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17: 3-14.
15. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al (2008) Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32: 412-419.
16. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-1707.
17. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
18. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71: 903-910.
19. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, et al (2013) Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154: 103-117.
20. Halliday GM, Holton JL, Revesz T, Dickson DW, (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122: 187-204.
21. Harding AJ, Halliday GM, (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102: 355-363.
22. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
23. Horvath R, Herrmann FR, Burkhard PR, Bouras C, Kovari E, (2013) Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord 19: 864-868.
24. Irwin DJ, Lee VM, Trojanowski JQ, (2013) Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14: 626-636.
25. Jellinger KA, Attems J, (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257: 80-87.
26. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM, (2011) Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis 4: 377-384.
27. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG, (2001) Age-dependent changes in brain, CSF, and plasma amyloid beta protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
28. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS, (2012) Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 69: 1326-1331.
29. Kovari E, Horvath J, Bouras C, (2009) Neuropathology of Lewy body disorders. Brain Res Bull 80: 203-210.
30. Leverenz JB, Miller MA, Dobie DJ, Peskind ER, Raskind MA, (2001) Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies. Neurobiol Aging 22: 555-561.
31. Lippa CF, Ozawa K, Mann DA, Ishii K, Smith TW, Arawaka S, Mori H, (1999) Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol 56: 1111-1118.
32. Masliah E, Rockenstein R, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L, (2001) Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98: 12245-12250.
33. McKeith IG, Burn DJ, Ballard CG, Collerton D, Jaros E, Morris CM, et al (2003) Dementia with Lewy bodies. Semin Clin Neuropsychiatry 8: 46-57.
34. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al (2005) Diagnosis and management of dementia with Lewy bodies-third report of the DLB consortium. Neurology 65: 1863-1872.
35. Meeus B, Theuns J, Van BC, (2012) The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol 69: 1113-1118.
36. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60: 1586-1590.
37. Mirra SS, Hart MN, Terry RD, (1993) Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 117: 132-144.
38. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SH, Hurtig H, Duda JE, et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114: 221-229.
39. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD, (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
40. Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA, (2012) A-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79: 1161-1167.
41. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD, (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem 61: 1916-1926.
42. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68: 1718-1725.
43. Schneider JA, Arvanitakis Z, Lu Y, Boyle PA, Leurgans SE, Bennett DA, (2013) Cognitive impairment, decline and fluctuations in older community dwelling subjects with Lewy bodies. Brain 135: 3005-3014.
44. Takahashi RH, Almeida CG, Kearney PF, Yu FM, Lin MT, Milner TA, Gouras GK, (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24: 3592-3599.
45. Thal DR, Rub U, Orantes M, Braak H, (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800.
46. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ, (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30: 552-557.
47. Ward RV, Jennings KH, Jepras R, Neville W, Owen DE, Hawkins J, et al (2000) Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem J 348: 137-144.
48. Whitfield DR, Vallortigara J, Alghamdi A, Howlett DR, Hortobágyi T, Johnson M, et al (2014) Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol Aging doi: 10.1016/j.neurobiolaging.2014.06.015.
49. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA, (2010) Neurodegenerative basis of age-related cognitive decline. Neurology 75: 1070-1078.